115 Quick summary: Researchers have identified that the protein cFLIP acts as a critical roadblock to cell death in aggressive blood cancers, particularly within the ABC–DLBCL subtype that often resists standard immunochemotherapy. By discovering that this protein allows tumours to evade both internal and external triggers for destruction, the study provides a vital proof of principle for developing new drugs that can re-sensitise cancer cells to programmed death. These findings offer a significant breakthrough for healthcare practice and public policy by highlighting a targeted pathway to improve survival outcomes for the 40% of patients who currently fail to respond to frontline treatments. A research team at the University of Cologne’s Center for Molecular Medicine Cologne (CMMC) has discovered that the protein cFLIP can override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. These defences often render treatments ineffective by allowing cancer cells to survive. The findings are particularly relevant to ABC–DLBCL, a subtype of the blood cancer associated with poor prognosis and survival outcomes. The study, titled “Expression of cFLIP in B cells is essential for diffuse large B cell lymphoma pathogenesis”, has been published in the journal Blood. DLBCL is the most common form of non-Hodgkin lymphoma, a cancer that develops from white blood cells known as lymphocytes. Standard frontline immunochemotherapy, which combines the antibody rituximab with chemotherapy agents, cures around 60% of patients. However, approximately 50% of treated patients either relapse or fail to respond, making further therapy difficult and risky. This highlights the urgent need for alternative treatments by identifying vulnerabilities in DLBCL cells. Such efforts are complicated by the disease’s heterogeneity and the ability of DLBCL cells to evade programmed cell death, or apoptosis, by overexpressing the anti-apoptotic factor BCL2. This survival mechanism allows lymphoma cells to proliferate indefinitely and form tumours, with serious consequences for patient outcomes. Understanding how cell death is regulated in these cells, and how to overcome the apoptosis blockade caused by BCL2 overexpression, is therefore critical. BCL2 tightly regulates the intrinsic pathway of apoptosis. Cells can also undergo extrinsic apoptosis, which is controlled by the cFLIP protein. The research team, led by Dr Alessandro Annibaldi at the CMMC, found that DLBCL cells overexpress not only BCL2 but also cFLIP. This dual overexpression blocks both intrinsic and extrinsic apoptotic pathways, making the cells highly resistant to death. “DLBCL cells build roadblocks to interrupt the intrinsic and extrinsic cell death avenues to try to reach immortality and gain a survival advantage over normal cells. Our goal was to identify and then remove the roadblock on the extrinsic apoptosis avenue, to re-programme the fate of these cells and push them to travel along the avenue that eventually leads to their death. The existence of such a roadblock has been hypothesised for many years, but our group was the first to find it and understand its clinical relevance,” says Alessandro Annibaldi. The team used advanced cell and molecular biology techniques alongside a preclinical mouse model of DLBCL. Their results show that targeting cFLIP can overcome the apoptosis blockade caused by BCL2 overexpression and restore cell death in lymphoma cells. They also found that cFLIP is specifically overexpressed in ABC–DLBCL and that its genetic deletion prevents lymphoma development by re-sensitising cells to death signals. These findings provide proof of principle that the extrinsic apoptosis pathway can be exploited to overcome resistance to cell death driven by BCL2 overexpression. The study supports the development of drugs targeting cFLIP, which could be used alone or in combination with existing therapies to eliminate ABC–DLBCL cells, regardless of their underlying mutations, provided they express cFLIP. Looking ahead, the researchers believe that developing cFLIP-specific inhibitory molecules and testing them in preclinical models will further clarify the translational potential of this approach. “Targeting cFLIP in combination with existing therapies represents a viable option worth exploring for patients unresponsive to DLBCL standard treatment,” says Kristie Bariboloka, the doctoral researcher who led the study.